Loading stock dataβ¦
$8.20+0.13 (+1.67%)
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction.
Q32 Bio Inc. in the Healthcare sector is trading at $8.20 with a market capitalization of $319M. Wall Street consensus targets $39.67 (6 analysts), implying a +384.0% move over the next 12 months. The stock is currently 65% below its 52-week high of $23.57, remaining 8.2% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0β | $53.74M | $0 | $0 |
| Gross Profit | β | β | β | β | β |
| Operating Income | -$9.12Mβ | -$7.72Mβ | $45.88Mβ | -$7.58Mβ | -$9.17M |
| Net Income | -$8.95Mβ | -$7.61Mβ | $57.73Mβ | -$7.39Mβ | -$9.49M |
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is...